Logo

Dr. Reddy's Tosymra (sumatriptan nasal spray) 10mg Receives the US FDA Approval for Acute Treatment of Migraine

Share this
Dr. Reddy's Tosymra (sumatriptan nasal spray) 10mg Receives the US FDA Approval for Acute Treatment of Migraine

Tuba Khan

Dr. Reddy's Tosymra (sumatriptan nasal spray) 10mg Receives the US FDA Approval for Acute Treatment of Migraine

Shots:
  • The approval is based on the clinical trial assessing Tosymra in patients with a migraine and demonstrated well tolerated and safe results
  • Promius Pharma’s (subsidiary of Dr. Reddy) Tosymra (previously known as DFN-02) is a nasal spray developed using Intravail platform- targeted to treat adults with migraine with or without aura- to achieve equivalent blood level developed with the usage of 4-mg sumatriptan SC injection
  • Intravail is a non-invasive drug delivery technology enabling delivery of multiple proteins- peptides and non-peptide drugs offering oral and buccal including dermal- and intranasal routes of drug administration
Click here  to read full press release/ article | Ref: Dr. Reddy | Image: Twitter      

Click Here

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family